Incidence of Decompensated Chronic Liver Disease in PFIC 3
The specific incidence of decompensated chronic liver disease (DCLD) in PFIC 3 is not precisely quantified in the available evidence, but the natural history indicates that severe MDR3 deficiency typically progresses to biliary cirrhosis with significant portal hypertension and liver failure, with approximately 35% requiring liver transplantation and mortality occurring from decompensated cirrhosis in documented cohorts.
Natural History and Disease Progression
The natural history of PFIC 3 (MDR3 deficiency) is characterized by moderate chronic cholestasis that leads to:
- Growth failure
- Pruritus
- Fat-soluble vitamin deficiencies
- Development of biliary cirrhosis
- Significant portal hypertension
- Liver failure 1
The disease course is highly variable and depends critically on genotype. Patients carrying at least one missense variant demonstrate better outcomes compared to those with biallelic protein-truncating variants 1.
Quantifiable Outcome Data
In a retrospective cohort of 67 adult carriers with heterozygous ABCB4 variants treated with UDCA:
- Transplant-free survival: 91% at median follow-up of 14 years
- Mortality: 3 patients died - two from cholangiocarcinoma and one from decompensated biliary cirrhosis
- 75% maintained normal liver stiffness (<6.3 kPa), suggesting disease stabilization 1
In pediatric series, 35.3% of PFIC patients required liver transplantation when significant fibrosis and portal hypertension developed 2.
Critical Prognostic Factors
Genotype-phenotype correlation is essential:
- Patients with at least one missense variant show better response to UDCA and longer native liver survival
- Those with biallelic protein-truncating variants demonstrate poor or no response to UDCA 1
Treatment compliance is paramount: Non-compliance with UDCA has been shown to result in abnormal liver tests and likely decreases native liver survival 1.
Clinical Heterogeneity
The phenotypic heterogeneity is substantial. Some patients present in early childhood with rapid progression, while others may have relatively indolent disease courses extending into the fourth decade 3. One case report documented a 40-year-old woman with slow progression to compensated cirrhosis, demonstrating the wide spectrum of disease severity 3.
Monitoring Requirements
Patients diagnosed at the stage of decompensated cirrhosis or those evolving toward end-stage liver disease require close monitoring for complications including:
- Ascites
- Esophageal/gastric variceal bleeding
- Hepatic encephalopathy 1
Most PFIC patients ultimately become candidates for liver transplantation despite medical management 4, 5.
Key Clinical Pitfall
PFIC 3 may masquerade as primary hematologic disorders, presenting with anemia, hepatosplenomegaly, and recurrent bleeding from portal hypertension before cholestatic features become apparent 6. This can significantly delay diagnosis and appropriate management.